RFI for Biosimilar Insulin Production

The Oklahoma State Department of Health (OSDH) is seeking input from pharmaceutical manufacturers producing or manufacturing fast-acting biosimilar insulin. The purpose of this Request for Information (RFI) is to obtain information for the Insulin Access and Affordability Program. The RFI includes questions about the manufacturer's intention to produce low-cost biosimilar insulin, the time frame for availability, geographic location of manufacturing, and estimated savings to Oklahoma residents and payors. • The RFI is for informational purposes only and will not be evaluated. • Responses should not include proprietary information as they may be made public. • The RFI does not extend any rights to prospective vendors or obligate the state to conduct a solicitation or purchase any goods or services.